

# Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion

NCT07315204

---

**Status** RECRUITING  
**Sponsor** The Cleveland Clinic  
**Enrollment** 850 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Age  $\geq$  18 years
- Any graft type (DBD or DCD)
- Any underlying recipient disease (i.e., end stage, liver tumour)
- Any other donor risk factors and static cold storage time prior to NMP accepted by the participating center for transplantation in context of OrganOx metra use
- Patients undergoing primary deceased donor liver transplantation where back-to-base NMP is used (OrganOx metra) from July 15, 2025 to December 31, 2027. (CCF only)
- ... and 1 more (see full listing online)

### Exclusion (6)

- Patients receiving a liver graft that is not perfused with OrganOx metra
- Pediatric recipients ( $\lt$  18 years)
- Patients listed for super urgent liver transplantation due to acute liver failure
- Patients receiving combined organ transplant (heart+liver, lung+liver, liver+kidney, liver+intestine)
- Patients receiving living donor liver transplant or a split (or reduced) liver transplantation or a domino graft.
- ... and 1 more (see full listing online)

## Locations (1 total)

---

Cleveland Clinic Foundation, Cleveland, Ohio, United States

---

<https://clinicaltrials.gov/study/NCT07315204>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).